Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

Equipping our people leaders to drive an inclusive organisation

By Mary O’Reilly (pictured) and Nikki O’Hanlon

- PMLiVE

Listen, learn and lift off

By Danny Buckland

- PMLiVE

Virtually present: how to hear every voice in a hybrid setting

By Shaun Beedle

- PMLiVE

Let them eat peanut butter on toast – why HCPs value familiarity over something new

By Kirsty Mead

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

regeneron headquarters

Regeneron set to acquire Checkmate for approximately $250m

The deal is expected to be finalised in mid-2022

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

Ad tracking: the end of the road?

As digital marketers, we’ve been closely monitoring the privacy debates between Apple, Facebook and Google over the last two years.

11 London

Top 10 Tips for Optimizing Asynchronous Virtual Meetings

We recently shared our top-10 creative ways to engage your advisors and most important advisor questions. In Impetus Digital’s third top-10 list, we focus on how to optimize asynchronous virtual...

Impetus Digital

Leveraging Real-Time Health Data for Proactive, Predictive Care

Alex Gilbert, Head of Digital Medicines Development & Life Sciences Partnerships at Huma, explores virtual & decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking...

Impetus Digital

- PMLiVE

Listen, learn and lift off

In April’s PME, Danny Buckland has been talking to industry leaders about launch excellence in the featured article, Listen, learn and lift off.Buckland points out that pandemic storms have changed the...

Lucid Group Communications Limited

- PMLiVE

AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19

The drug decreases the risk of developing symptomatic COVID-19 by 77% among high-risk populations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links